Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners upped their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $0.18 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The firm has a market capitalization of $537,480.00, a P/E ratio of 0.00 and a beta of 2.08. The business has a fifty day moving average of $0.22 and a 200 day moving average of $2.17. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. The company had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. As a group, sell-side analysts anticipate that Tonix Pharmaceuticals will post -18 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC raised its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.